Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Many US employers plan to pare health benefits as weight-loss spending soars - Nation and World News | Hawaii Tribune-Herald ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...